JP2020513745A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513745A5 JP2020513745A5 JP2019532044A JP2019532044A JP2020513745A5 JP 2020513745 A5 JP2020513745 A5 JP 2020513745A5 JP 2019532044 A JP2019532044 A JP 2019532044A JP 2019532044 A JP2019532044 A JP 2019532044A JP 2020513745 A5 JP2020513745 A5 JP 2020513745A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- cancer
- fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 23
- 102000036639 antigens Human genes 0.000 claims 23
- 108091007433 antigens Proteins 0.000 claims 23
- 239000012634 fragment Substances 0.000 claims 23
- 206010016654 Fibrosis Diseases 0.000 claims 16
- 230000004761 fibrosis Effects 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 210000000056 organ Anatomy 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- 230000000069 prophylactic effect Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000021908 Myocardial disease Diseases 0.000 claims 2
- 208000031472 Retinal fibrosis Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 210000002249 digestive system Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 108040006873 interleukin-11 receptor activity proteins Proteins 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 230000000938 luteal effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000002346 musculoskeletal system Anatomy 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 208000003663 ventricular fibrillation Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1621439.7A GB201621439D0 (en) | 2016-12-16 | 2016-12-16 | IL-11Ra Antibodies |
| GB1621439.7 | 2016-12-16 | ||
| PCT/EP2017/083043 WO2018109170A2 (en) | 2016-12-16 | 2017-12-15 | Il-11ra antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020513745A JP2020513745A (ja) | 2020-05-21 |
| JP2020513745A5 true JP2020513745A5 (enExample) | 2021-01-28 |
| JP7175271B2 JP7175271B2 (ja) | 2022-11-18 |
Family
ID=58284610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532044A Active JP7175271B2 (ja) | 2016-12-16 | 2017-12-15 | ＩＬ－１１Ｒα抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20180186872A1 (enExample) |
| EP (1) | EP3555135B1 (enExample) |
| JP (1) | JP7175271B2 (enExample) |
| KR (1) | KR20190111924A (enExample) |
| CN (1) | CN110337447B (enExample) |
| AU (1) | AU2017378107A1 (enExample) |
| BR (1) | BR112019012343A2 (enExample) |
| CA (1) | CA3046848A1 (enExample) |
| GB (1) | GB201621439D0 (enExample) |
| MX (1) | MX2019007021A (enExample) |
| TW (1) | TW201829465A (enExample) |
| WO (1) | WO2018109170A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522186D0 (en) | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
| CA3045871A1 (en) | 2016-12-16 | 2018-06-21 | Singapore Health Services Pte Ltd | Il-11 antibodies |
| GB201809700D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| CN109053882B (zh) * | 2018-08-28 | 2019-08-23 | 东莞市朋志生物科技有限公司 | 一种ns1蛋白的结合蛋白以及应用 |
| AU2020211695A1 (en) | 2019-01-21 | 2021-09-02 | National University Of Singapore | Treatment of hepatotoxicity |
| GB201902419D0 (en) | 2019-02-22 | 2019-04-10 | Singapore Health Serv Pte Ltd | Treatment of kidney injury |
| CN114364693A (zh) | 2019-05-03 | 2022-04-15 | 新加坡保健服务私人有限公司 | 代谢性疾病的治疗和预防 |
| GB201906291D0 (en) | 2019-05-03 | 2019-06-19 | Singapore Health Serv Pte Ltd | Treatment and prevention of metabolic diseases |
| RU2722398C1 (ru) * | 2019-08-09 | 2020-05-29 | Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства | Моноклональное антитело к БТШ70 |
| GB202009292D0 (en) | 2020-06-18 | 2020-08-05 | Singapore Health Serv Pte Ltd | Treatment and prevention of disease caused by type IV collagen dysfunction |
| GB202017244D0 (en) | 2020-10-30 | 2020-12-16 | Nat Univ Singapore | Methods to extend health-span and treat age-related diseases |
| WO2022109403A1 (en) * | 2020-11-23 | 2022-05-27 | Scout Bio, Inc. | Antigen-binding molecules and uses thereof |
| CA3211686A1 (en) | 2021-02-26 | 2022-09-01 | Bayer Aktiengesellschaft | Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding |
| US20240218069A1 (en) * | 2021-04-28 | 2024-07-04 | Lyvgen Biopharma Holdings Limited | Bi-specific antibodies comprising anti-b7h3 binding molecules |
| JP2024526944A (ja) | 2021-07-26 | 2024-07-19 | ベーリンガー・インゲルハイム・インターナショナル・ゲーエムベーハー | アルコール性肝疾患の処置および予防 |
| WO2023034809A1 (en) | 2021-08-30 | 2023-03-09 | Lassen Therapeutics 1, Inc. | Anti-il-11rα antibodies |
| CN113735975B (zh) * | 2021-09-07 | 2022-08-12 | 广东东阳光药业有限公司 | 一种抗il-11r抗体及其应用 |
| EP4448096A1 (en) | 2021-12-16 | 2024-10-23 | Singapore Health Services Pte. Ltd. | Treatment and prevention of glomerular disease |
| CN116510007A (zh) * | 2022-01-29 | 2023-08-01 | 迈威(上海)生物科技股份有限公司 | 采用抗il-11抗体的肿瘤组合疗法 |
| CN120787238A (zh) * | 2023-01-06 | 2025-10-14 | 拉森医疗公司 | 用于治疗甲状腺眼病的抗IL-11Rα抗体 |
| WO2025255486A2 (en) * | 2024-06-07 | 2025-12-11 | Lassen Therapeutics, Inc. | DOSING OF ANTI-IL-11Rα ANTIBODIES IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS |
| WO2025255483A2 (en) * | 2024-06-07 | 2025-12-11 | Lassen Therapeutics, Inc. | DOSING OF ANTI-IL-11Rα ANTIBODIES IN THE TREATMENT OF THYROID EYE DISEASE |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE342970T1 (de) | 1994-12-22 | 2006-11-15 | Genetics Inst Llc | Verwendung eines menschlichen interleukin-11 rezeptors |
| US6126933A (en) | 1995-06-27 | 2000-10-03 | Genetics Institute | Methods of treating inflammatory bowel diseases by administering IL-11 |
| US5679339A (en) | 1995-06-27 | 1997-10-21 | Keith; James | Method of using IL-11 for treating spondyloarthropies |
| US6540993B1 (en) | 1995-06-27 | 2003-04-01 | Wyeth | Method of treating inflammatory bowel disease using a topical formulation of IL-11 |
| GB9702944D0 (en) | 1997-02-13 | 1997-04-02 | Univ Manchester | Reducing fibrosis |
| GB9721961D0 (en) | 1997-10-16 | 1997-12-17 | Glaxo Group Ltd | Novel molecules |
| CA2237915A1 (en) | 1998-05-19 | 1999-11-19 | Stephen Shaughnessy | Osteoporosis treatment |
| US6953777B2 (en) | 1999-03-11 | 2005-10-11 | Genetics Indtitute LLC | Use of interleukin-11 to prevent immune-mediated cytotoxicity |
| WO2000078336A1 (en) | 1999-06-21 | 2000-12-28 | Genetics Institute, Inc. | Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains |
| GB0021668D0 (en) | 2000-09-04 | 2000-10-18 | Smithkline Beecham Plc | New use |
| CN1688293A (zh) | 2002-09-16 | 2005-10-26 | 韦思公司 | 多肽治疗剂口服给药的缓释配方及其使用方法 |
| WO2005058956A1 (en) | 2003-12-16 | 2005-06-30 | Commonwealth Scientific And Industrial Research Organisation | Cytokine binding domains |
| US20060019890A1 (en) | 2004-01-15 | 2006-01-26 | Kapoun Ann M | Method for treating cardiac remodeling following myocardial injury |
| WO2005098041A2 (en) | 2004-03-26 | 2005-10-20 | University Of Florida Research Foundation, Inc. | Detection and treatment of fibrotic disorders |
| EP1630232B1 (en) | 2004-08-27 | 2008-07-02 | CONARIS research institute AG | Optimized nucleotide sequences encoding sgp130 |
| EP1957097A1 (en) | 2005-12-06 | 2008-08-20 | Wyeth a Corporation of the State of Delaware | Interleukin-11 compositions and methods of use |
| CN100441689C (zh) * | 2006-01-20 | 2008-12-10 | 中国人民解放军第三军医大学 | 抗ehec o157志贺样毒素ⅱa亚单位单克隆抗体5f3轻、重链可变区基因及应用 |
| US8361966B2 (en) | 2006-10-27 | 2013-01-29 | Osaka University | Use of interleukin-11 as therapeutic agent for heart disease |
| US8182814B2 (en) | 2007-10-26 | 2012-05-22 | Csl Limited | Methods of treating inflammatory airway conditions by inhibition of IL-11 activity |
| WO2009052588A1 (en) | 2007-10-26 | 2009-04-30 | Csl Limited | Cytokine muteins |
| US8518888B2 (en) | 2008-10-14 | 2013-08-27 | Csl Limited | Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R |
| KR101133769B1 (ko) | 2011-04-18 | 2012-04-09 | 한국생명공학연구원 | 신규한 옥사졸리딘계 및 인돌계 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물 |
| KR102489953B1 (ko) | 2013-02-07 | 2023-01-20 | 씨에스엘 리미티드 | Il-11r 결합 단백질 및 이의 용도 |
| CN103965357B (zh) * | 2013-12-31 | 2016-08-17 | 嘉和生物药业有限公司 | 一种抗人rankl抗体 |
| CN105497893B (zh) | 2015-12-10 | 2019-02-01 | 黑龙江省科学院高技术研究院 | IL-11单克隆抗体在抑制PI3K/Akt信号通路中的应用 |
| GB201522186D0 (en) | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| RU2016125115A (ru) | 2016-06-23 | 2017-12-28 | Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) | Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов |
| CA3045871A1 (en) | 2016-12-16 | 2018-06-21 | Singapore Health Services Pte Ltd | Il-11 antibodies |
| GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
| RU2016151730A (ru) | 2016-12-28 | 2018-06-29 | Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) | Антитела для лабораторной диагностики концентрации интерлейкина-11 |
| GB201809700D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| GB201809699D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
-
2016
- 2016-12-16 GB GBGB1621439.7A patent/GB201621439D0/en not_active Ceased
-
2017
- 2017-12-15 CA CA3046848A patent/CA3046848A1/en not_active Abandoned
- 2017-12-15 BR BR112019012343A patent/BR112019012343A2/pt not_active IP Right Cessation
- 2017-12-15 US US15/843,212 patent/US20180186872A1/en not_active Abandoned
- 2017-12-15 AU AU2017378107A patent/AU2017378107A1/en not_active Abandoned
- 2017-12-15 MX MX2019007021A patent/MX2019007021A/es unknown
- 2017-12-15 KR KR1020197020595A patent/KR20190111924A/ko not_active Ceased
- 2017-12-15 CN CN201780086784.6A patent/CN110337447B/zh active Active
- 2017-12-15 JP JP2019532044A patent/JP7175271B2/ja active Active
- 2017-12-15 TW TW106144202A patent/TW201829465A/zh unknown
- 2017-12-15 WO PCT/EP2017/083043 patent/WO2018109170A2/en not_active Ceased
- 2017-12-15 EP EP17836010.3A patent/EP3555135B1/en active Active
-
2019
- 2019-12-23 US US16/726,190 patent/US11078269B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511414A5 (enExample) | ||
| US10463627B2 (en) | Therapeutic nanoparticles and methods of use thereof | |
| Verweij et al. | Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analyis of EORTC-ISG-AGITG study 62005 | |
| JP2021175754A (ja) | がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ | |
| JP2019528061A5 (enExample) | ||
| Liu et al. | Immunotherapy and targeted therapy for cholangiocarcinoma: artificial intelligence research in imaging | |
| Thomas et al. | Advancing therapeutics in small-cell lung cancer | |
| US10577609B2 (en) | Glypican-3 specific aptamer and use thereof | |
| US20200390903A1 (en) | Plectin-targeted liposomes/parp inhibitor in the treatment of cancer | |
| US11149275B2 (en) | Device and method to treat esophageal disorders | |
| Akbulut et al. | Gastric bezoars | |
| Ahluwalia et al. | P07. 09. BA randomized phase 2B study of survivin vaccine survaxm plus adjuvant temozolomide for newly-diagnosed glioblastoma (survive) | |
| CN104777213A (zh) | 肌动蛋白结合蛋白2筛选平滑肌功能障碍疾病治疗药物的用途 | |
| Kuneš et al. | Pharmacokinetics and organ distribution of fluorescein in experimental pigs: an input study for confocal laser endomicroscopy of the gastrointestinal tract | |
| US20210079039A1 (en) | Compositions and methods for the selective delivery of therapeutic and imaging agents | |
| Gao et al. | A hepatic-targeted glycogen-based nano-platform enables efficient CTGF silencing and attenuates liver fibrosis | |
| US20220347306A1 (en) | Selective delivery of therapeutic and imaging agents | |
| Alabbas et al. | S2331 case report: a case of diffuse large B-cell lymphoma with gastrointestinal involvement | |
| Maljaars et al. | M2078 distribution of small intestinal fat delivery influences satiety and food intake | |
| Pomara et al. | Autonomic nervous system instability, tetanic necrosis of the heart and myocardial TNFα expression in a tetanus fatal case | |
| Hu et al. | Enhanced oral nanomedicine utilizing biomineralized oncolytic virus for synergistic gastrointestinal cancer therapy | |
| Trinh et al. | Drug Delivery in Retinoblastoma | |
| Moawad et al. | Comparison of Aerosolized Swallowed Fluticasone to Esomeprazole for the Treatment of Eosinophilic Esophagitis: 30 | |
| CN109195620A (zh) | 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法 | |
| Pironi et al. | OC. 10.4 Translating the assessment of plasma citrulline concentration in clinical practice |